PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ation unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are

Substitute for form 1449A/PTO

NFORMATION DISCLOSURE TATEMENT BY APPLICANT

(use as many sheets as necessary)

of

	C mplete if Kn wn				
Application Number	10/067,979				
Filing Date	2/8/02				
First Named Inventor Vincent Fischetti					
Group Art Unit	1651				
Examiner Name PRATS, FRANCISCO CHANDLE					
Attorney Docket Number					

			U.S. PATENT	OCUMENTS	
Examiner Cite		Cite Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Initials	No.	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
	1	US- 6056954	05/02/00	Fischetti, et al.	
HAI	2	US- 5997862	12/07/99	Fischetti, et al.	
	3	US- 5985271	11/16/99	Fischetti, et al.	
†	4	US- 5688501	11/18/97	Merril, et al.	
1	5	US- 4742981	05/10/88	Converse	RECEIVED
+ -	6	US- 2019789	11/05/35	Mahannah	I Ham for the I A from the
	7	US- 2763931	09/25/58	McMillan	11111-0-0-000
	8	US- 5479732	01/02/96	Burtch, et al.	100 8 8 2003
	9	US- 3465445	09/09/69	Fisher	
+	10	US- 2315260	03/30/43	Lancaster	TECH CENTER 1600/2
	11	US- 5604109	02/18/97	Fischetti, et al.	IEDII DEILIEILI INDO
-	12	US- 5260292	11/09/93	Robinson, et al.	
	13	US- 4957686	09/18/90	Norris	
	14	US- 6017528	01/25/00	Fischetti, et al.	
+	15	US- 8132970	10/17/00	Stemmer	
+	16	US- 3852424	12/03/74	Gaeumann, et al.	
1	17	US- 6264945	07/24/01.	Fischetti, et al.	
1 .	18	US- 6254866	07/03/01	Fischetti, et al.	
1/	19	US- 8248324	06/19/01	Fischetti, et al.	
- V -	20	US- 6238661	05/29/01	Fischetti, et al.	

***************************************		FOREIGN PA	TENT DOCU	MENTS		
		Foreign Patent Document	Publication Date MM-DD-YYYY Name of Palentee or Applicant of Cited Document	Name of Palentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			Passages or Relevant Figures Appear	T [®]
TO S	21	EP-0510907 A 2	10/28/92	Agricultural & Food Res.		
0 1 	22	WO-9702351	01/23/97	CIBA Geigy AG, et al.		
	23	WO-9607329	03/14/96	Univ. Maryland		
	24	WO-9904809	02/04/99	Ambi, Inc.		
	25	FR-2357246	02/03/78	Martinez		
1/	26	WO-9531562	11/23/95	Quest Inernational B.V.		
Ψ	27	EP-587541 A1	03/16/94	Tecnogen ScpA		
	<u> </u>					

4-22-04 Date Considered Examiner Signature

^{&#}x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control cumber.

stitute for form 1449A/PTO

STATE OF FORMATION DISCLOSURE ATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

oqui ac a respective de la constantina	Complete if Kn wn	HE	CEN
Application Number	10/067,979		CEIVED
Filing Date	2/8/02	JUN	
First Named Inventor	Vincent Fischetti	TECH	\$ 2003
Group Art Unit	1651	GATE CENTE	ä
Examiner Name	1651 PRATS, FRANCISCO	CHANDLERS	1 1600/200
Attorney Docket Number			9 1600/2900

			U.S. PATENT	OCUMENTS	
Examiner Initials	Cite No.	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	28	US- 6056955	05/02/00	Fischetti, et al.	
N/	29	US- 5882631	03/16/99	Suga, et al.	
VI ' -	30	US- 5741487	04/21/98	Asai, et al.	
-	31	US- 6113887	09/05/00	Mori, et al.	
	32	US- 4122158	10/24/78	Schmitt	
	33	US- 3983209	09/28/76	Schmitt	
	34	US- 4885163	12/05/89	Shaar, et al.	
\dashv	35	US- 6177554	01/23/01	Woo, et al.	
	36	US- 6187757	02/13/01	Clackson, et al.	
	37	US- 5162226	11/10/92	Beachey, et al.	
	38	US- 6335012	. 01/01/02	Fischetti, et al.	
	39	US- 6326002	12/04/01	Fischetti, et al.	
}	40	US- 6277399	08/21/01	Fischetti, et al.	* .
	41	US- 4062941	12/13/77	Davies	
	42	US- 5571667	11/05/96	Chu, et al.	
	43	US- 5514602	05/07/96	Brooks Jr, et al.	
	44	US- 5500350	03/19/96	Baker, et al.	
	45	US- 5384265	01/24/95	Kidwell, et al.	
1/	46	US- 4361537	11/30/82	Deutsch, et al.	
-₩	47	US- 5120643	06/09/92	Ching, et al.	

		FOREIGN PA	TENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	T [©]
iniuais	140.	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	MM-DD-YYYY		Figures Appear	<u>'</u>
	48	WO-9323544	11/25/93	The University Court of the University of Glasgow		
	49	EP-0293249 A1	11/30/88	Amrad Corporation Limited		,
	50	EP-0646646 A2	04/05/95	Bristol-Myers Squibb Company		
1/	51	EP-0359873 A1	03/28/90	The Public Health Research Inst. of the City of New York		
	 					<u> </u>

	1/2/		
Examiner Signature	1100	Date Considered	4-22-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are

ibstitute for form 1449A/PTO

或FORMATION DISCLOSURE ATEMENT BY APPLICANT

(use as many sheets as necessary)

of 11 Sheet

	PTO/SB/08A (10-01)	
U.S. Patent and Trade	proved for use through 10/31/2002. OMB 0651-0031 emark Office: U.S. DEPARTMENT OF COMMERCES	
equired to respond to a collection of	f information unless it contains a valid OMB control number	
	Compl te if Known	
Application Number	Compl te if Known 10/067,979	ン
Filing Date	2/8/02 ECH 20	
First Named Inventor	Vincent Fischetti	
Group Art Unit	1651	
Examiner Name	PRATS, FRANCISCO CHANDLER	

			U.S. PATENT	OCUMENTS	
Examiner nitials	Cite No.1	Document Number Number - Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	52	US-4948726	08/14/90	Longoria	
	53	US- 4459361	07/10/84	Gefter	
	54	US- 4552839	11/12/85	Gould, et al.	
	55	US- 4313734	02/02/82	Leuvering	
	56	US- 4847199	07/11/89	Snyder, et al.	
	57	US- 4497900	02/05/85	Abram, et al.	
t	58	US- 4707543	11/17/87	Zollinger, et al.	
	59	US- 5763251	06/09/98	Gasson	
	60	US- 6159688	12/12/00	Borchert, et al.	
	61	US- 4784948	11/15/88	Scott, et al.	
	62	US- 5760026	06/02/98	Blackburn, et al.	
	63	US- 5602040	02/11/97	May, et al.	
l	64	US- 4521252	06/04/85	Miyake, et al.	
 	65	US- 4355022	10/19/82	Rabussay	
 	66	US- 4115546	09/19/78	Vidra, et al.	
	67	US- 4116327	09/26/78	Eglinton, et al.	
1	68	US- 3929994	12/30/75	Hirsch, et al.	
1/	69	US- 6083684	07/04/00	Gasson	
1/	70	US- 5360617	11/01/94	Gasson	
₩/	71	US- 5079174	01/07/92	Buck, et al.	

	FOREIGN PATENT DOCUMENTS						
	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T°	

Examiner Signature	ON las	Date Considered	4-22-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-033
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCIF.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Form 1449A/PTO

C mplete if Known

Application Number 10/067,979

Filing Date 2/8/02

Vincent Fischetti Substitute for form 1449A/PTO **MFORMATION DISCLOSURE** TEMENT BY APPLICANT (use as many sheets as necessary)

Attorney Docket Number

U.S. PATENT DOCUMENTS					
Braminer:	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
nitials	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
KY X	72	US- 5604110	· 02/18/97	Baker, et al.	
U	73	US- 5294369	03/15/94	Shigekawa, et al.	
	74	US- 5372931	12/13/94	Friedman, et al.	
	75	US- 4933185	06/12/90	Wheatley, et al.	
	76	US- 5108758	04/28/92	Allwood, et al.	
	77	US- 4713249	12/15/87	Schroder	
	78	US- 4812445	03/14/89	Eden, et al.	
	79	US- 3622677	11/23/71	Short, et al.	
17	80	US- 4369308	01/18/83	Trubiano ·	
	81	US- 5393658	02/28/95	Olsen	
		US-			

	FOREIGN PATENT DOCUMENTS						
Cumina	0.11	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
	Cite No.1 Country C	Country Code ² - Number ⁴ - Kind Code ⁵ (if known) Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰		

4-22-04 Examiner Date Signature Considered

Sheet

of

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons	U.S. Patent and Trac	oproved for use through 10/31/ lemark Office: U.S. DEPARTM of information unless it contains a	ENT OF COMMERCE
r form 1449A/PTO		C mplete if Kn wn	MEGENI
MATION BIOOL COURT	Application Number	10/067,979	VEr
MATION DISCLOSURE	Filing Date	2/8/02	2014
MENT BY APPLICANT	First Named Inventor	Vincent Fischetti	ECH (19. 2003
	Croup Art Unit	1651	UENTER

PRATS, FRANCISCO CHANDLER

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	82	KH Nasibulini et al; RU-2103991; Composition for treating streptococcal diseases - comprises purified concentrate of streptococcal bacteriophage, solution of quinsosol, dry lanolin, albumin and vegetable oil; XP-002141110	
2/	83	LD Demidova et al; RU2064299; Cattle mastitis therapeutic preparation - comprises lyso: amidase of specific lytic activity and mono- and di-basic sodium phosphate(s); XP-002141111	
J '			
		·	
		7	
Examiner Signature	1	Date Considered 4-22-04	

Examiner Name

Attorney Docket Number

itute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 11

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF GOMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control of the contains and the contains and the contains and the contains are required to respond to a collection of information unless it contains a valid OMB control of the contains and the contains are required to respond to a collection of information unless it contains a valid OMB control of the contains and the contains a valid OMB control of the contains and the contains and the contains are required to respond to a collection of information unless it contains a valid OMB control of the contains and the contains are required to respond to a collection of information unless it contains a valid OMB control of the contains and the contains are required to respond to a collection of information unless it contains a valid OMB control of the contains and the contains are required to respond to a collection of information unless it contains a valid OMB control of the contains are required to respond to a collection of information unless it contains a valid OMB control of the contains and the contains are required to respond to a collection of information unless it contains a valid OMB control of the contains are required to respond to a collection of information unless it contains and the contains are required to respond to the contains and the contains are required to respond to the contains and the contains are required to respond to the contains and the contains are required to respond to the contains are required to respond to the contains are required to the contains and the contains are required to the contain

stitute for form 1449A/PTO

NFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/067,979 Filing Date 2/8/02 Vincent Fischetti First Named Inventor 1651 **Group Art Unit** PRATS, FRANCISCO CHANDLER **Examiner Name**

(use as many sheets as necessary)

Attorney Docket Number of 11 Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Ell	84	BABENKO et al. Enzymatic lysis of staphylococci in relation to their species and strain properties, 1990, Database Medline Online, US National Library of Medicine, Bethesda, MD, US, Database Accession No. 90297672 XP002170795, abstract only	
	85	BARTELL, et al., Origin of polysaccharide depolymerase associated with bacteriophage infection, Journal of Virology, March 1969, pp. 290-296, Vol. 3, No. 3	
	86	BEHNKE, et al., Cloning and expression in Escherichia coli, Bacillus subtilis and Streptococcus sanguis of a gene for staphylokinase - a bacterial plasminogen activator, Mol Gen Genet, December 1987, pp. 528-534, Vol. 210	
	87	BESSEN, et al., Chemical characterization of binding properties of opacity-associated protein II from Neisserla gonorrheae, Infection and Immunity, January 1987, pp. 141-147, Vol. 55, No. 1	
	88	BIZIULEVICHIUS, et al., In vivo studies on lysosubtilin: 3. Efficacy for treatment of mastitis and superficial lesions of the udder and teats in cows, 1998, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US, Database Accession No. PREV199800492606, XP002183274, abstract only	- 1500No
	89	BOIZET, et al., Cloning, expression and sequence analysis of an endolysin-encoding gene of Lactobacillus bulgaricus bacteriophage mv1, Gene, 2000, pp. 61-67, Vol. 94	
	90	CALDWELL, et al., Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis, Infection and Immunity, March 1981, pp. 1161-1176, Vol. 31, No. 3	
	91	YOUNG et al. Phages will out: strategies of host cell lysis, Trends in Microbiology, Volume 8 No. 3, March 2000, pp 120-127	
	92	CORBEL, et al., Soluble antigens obtained from influenza virus by treatment with non-lonic detergent, J Hyg.,Camb., 1970, pp. 81-96, Vol. 68	
1	93	CROUX, et al., Interchange of functional domains switches enzymes specificity: construction of a chimeric pneumococcal-clostridial cell wall lytic enzyme, Molecular Microbiology, 1993, pp.1019-25, Vol. 9, No. 5	
	94	DIAZ, et al., Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes, Proc. Natl. Acad. Sci. USA, October 1990, pp. 8125-8129, Vol. 87	

	· · · · · · · · · · · · · · · · · · ·		
Examiner Signature	Plat	Date Considered	4-22-04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B	(10-01)

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ute for form 1449A/PTO NFORMATION DISCLOSURE

C mpl t if Known **Application Number** 10/067,979 Filing Date 2/8/02 First Named Inventor Vincent Fischetti 1651 TECH AFAINDLE
PRATS, FRANCISCO CHANDLE Group Art Unit

(use as many sheets as necessary)

STATEMENT BY APPLICANT

Examiner Name of 11 Attorney Docket Number Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Cite		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PO	95	DIAZ, et al., Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits, Journal of Biological Chemistry, March 25, 1991, pp. 5464-5471, Vol. 266, No. 9	
	96	DIXON, et al., Lysostaphin: an enzymatic approach to staphylococcal disease. III. Combined lysostaphin- methicillin therapy of established staphylococcal abcesses in mice, The Yale Journal of Biology and Medicine, August 1968, pp. 62-68, Vol. 41, No. 1	
	97	FISCHETTI, et al., Size variation of the M protein in group A streptococci, Journal of Exp. Med., June 1, 1985, pp. 1384-1401, Vol. 161, No. 6	
	98	GARCIA, et al., Bacteriophages of Streptococcus pneumoniae: A molecular approach, Microbial Drug Resistance, Summer 1997, pp. 165-176, Vol. 3, No. 2	
	99	GARCIA, et al., Cloning, purification and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin, Journal of Virology, August 1987, pp. 2573-2580, Vol. 61, No. 8	
	100	GARCIA, et al., Modular organization of the lytic enzymes of streptococcus pneumoniae and its bacteriophages, Gene, 1990, pp. 81-88, Vol. 86	
	101	GERARDY-SCHANN, et al., Molecular cloning and functional expression of bacteriophage PK1E-encoded endoneuraminidase Endo NE, Molecular Microbiology, May 1995, pp. 441-450, Vol. 16, No. 3	
	102	GOLDBERG, et al., Studies in experimental staphylococcal endocarditis in dogs, Antimicrobial Agents and Chemotherapy, 1967, pp. 45-53	
	103	HARRISON, et al., Lysostaphin in experimental renal infections, Journal of Bacteriology, February 1967, pp. 520-524, Vol. 93, No. 2	
	104	HARRISON, et al., Therapeutic activity of lysostaphin in experimental staphylococcal infections, Canadian Journal of Microbiology, January 1987, pp. 93-97, Vol. 13, No. 1	
V	105	HAYASHI, et al., Effects of N-Acetylmuramidase from Streptomyces rutgersensis H-46 as a food preservative, Agric. Biol. Chem., December 1989, pp. 3173-3177, Vol. 53, No. 12	

Examiner Signature	Celled	Date Considered	4.22 04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

titute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

C mplete if Known **Application Number** 10/067,979 Filing Date 2/8/02 Vincent Fischetti First Named Inventor 1651 **Group Art Unit** PRATS, FRANCISCO CHANDLER **Examiner Name**

(use as many sheets as necessary)

TRATE THA

of 11 Attorney Docket Number Sheet 8

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-isses number(s), publisher, city and/or country where published.		Τ²
SI	106	HAYASHIDA, et al., Further characterization of PL-1 phage associated N-acetylmuramidase of Lactobacillus casei, Journal of General Microbiology, May 1987, pp. 1343-1349, Vol. 133, No. 5	
	107	HIGUCHI, et al., Transfection of streptococcus sanguis by phage deoxyribonucleic acid isolated from streptococcus mutans, Infection and Immunity, March 1977, pp. 945-949, Vol. 15, part 3	
	108	HUAN, et al., Methicillin-resistant staphylococcus aureus infection and its treatment in burned patients, Chinese Journal of Surgery, 1994, Vol. 32, No. 4, abstract	
	109	HUGHEY, et al., Antimicrobial activity of lysozome against bacteria involved in food spoilage and food-borne disease, Applied and Environmental Microbiology, September 1987, pp. 2165-2170, Vol. 53, No. 9	
	110	KOHLER, Systemic therapy with aerosols Aerosols in Medicine: Principles, Diagnosis and Therapy, 1993, Elseveir Science Publishers, pp. 303-319	
	111	LAWMAN, et al., Molecular cloning of the extracellular endodextranase of streptococcus salivarius, Journal of Bacteriology, December 1991, pp. 7423-7428, Vol. 173, No. 23	
	112	LOESSNER, et al., Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of staphylococcus aureus bacteriophage 187, Journal of Bacteriology, August 1999, pp. 4452-4460, Vol. 181, No. 15	
	113	LOESSNER, et al., Modified listeria bacteriophage lysin genes (ply) allow efficient overexpression and one - step purification of blochemically active fusion proteins, Applied and Environmental Microbiology, August 1996, pp. 3057-3060, Vol. 62, No. 8	
	114	LOPEZ, et al., Architecture and domain interchange of the pneumococcal cell wall lytic enzymes, Genetics of Streptococci, Enterococci and Lactococci, Developments in Biological Standardization, 1995, pp. 273-281, Vol. 85	
	115	LOPEZ, et al., The pneumococcal cell wall degrading enzymes a modular design to create new lysins, Microbial Drug Resistance, November 2, 1997, pp. 199-211, Vol. 3, No. 2	
V	116	MARTIN, et al., Functional analysis of the two-gene lysis system of the pnemococcal phage Cp-1 in homologous and heterologous host cells, Journal of Bacteriology, January 1998, pp. 210-217, Vol. 180, No. 2	

Examiner Signature	Pellas	Date Considered	4-22-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB country number

FORMATION DISCLOSURE STATEMENT BY APPLICANT

Compl te if Known Application Number 10/067,979 Filing Date 2/8/02 Vincent Fischetti First Named Inventor Group Art Unit 1651 PRATS, FRANCISCO CHANDLER **Examiner Name**

(use as many sheets as necessary)

tute for form 1449A/PTO

Attorney Docket Number of 11 Sheet

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials)	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
BLY	1 17	MUKHLIS, et al., Characterization and Immunogenicity of HSV-1 antigens obtained following zwitteronic detergent treatment; Vaccine, September 1986, pp. 191-196, Vol. 4			
	118	NELSON, et al., Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme, PNAS, March 27, 2001, pp. 4107-4112, Vol. 98, No. 7			
	119	NELSON, et al., Selective and rapid killing of group A streptococci using a muralytic enzyme, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US and abstracts of the General Meeting of the American Society for Microbiology, 2000, pp. 32-33			
	120	OKI, et al., Functional and structural features of the holin HOL protein of the Lactobacillus plantarum phage analysis in escherichia coli system, Gene, 1997, pp. 137-145, Vol. 197			
	121	OKUHARA, et al., Preparation of group A streptococcal cell membranes by treatment with group C streptococcus phage - associated lysin, Annales Paediatrici Japonici, June 1983, pp. 10-19, Vol. 29, No. 2			
	122	PATTON, et al., Routes of delivery: case studies, Pulmonary delivery of peptides and proteins for systemic action, Advanced Drug Delivery Reviews, 1992, pp. 179-196, Vol. 8			
	123	POLAK, et al., In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant staphylococcus aureus, Diagn. Microbiol. Infect. Dis., 1993, pp. 265-270, Vol. 17			
	124	RAINA, Purification of streptococcus group C bacteriophage lysin, Journal of Bacteriology, January 1981, pp. 661-663, Vol. 145, No. 1			
	125	RONDA, et al., Infection of streptococcus oralis NCTC 11427 by pneomococcal phages, FEMS Microbiology Letters, 1989, pp. 187-192, Vol. 65			
/	126	SANZ, et al., Construction of a multifunctional pneumococcal murein hydrolase by module assembly, Eur. J. Biochem., February 1, 1996, pp. 601-605, Vol. 235, No. 3			
	127	SATO, et al., Partial characterization of n - Butanol - solubilized rejection - type antigens of syngeneic murine colon tumors, JNCI, April 1985, Vol. 74, No. 4			

Examiner Signature	De	las	0	Date Considered	4.22.04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

. PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitute for form 1449A/PTO

Sheet

MFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of 11

	Complete if Known	BEO.	
Application Number	10/067,979	"CCEIVE	٠,
Filing Date	2/8/02	1114	L
First Named Inventor	Vincent Fischetti	2 6 2000	
Group Art Unit	1651 /EC/	4000	
Examiner Name	PRATS, FRANCISC	O CHANGRERS	
Attorney Docket Number			אמנ

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
K	128	SHEEHAN, et al., Analysis of the catylytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling; FEMS Microbiology Letters, 1996, pp. 23-28, Vol. 140	
Sil	129	SHEEHAN, et al., The lytic enzyme of the pneumococcal phage Dp-1: A chlmeric lysin of intergeneric origin, Molecular Microbiology, 1997, pp. 717-725	
621	130	WITTE, et al., Characterization of escherichia coli lysis using a family of chimeric E-L genes, FEMS Microbiology Letters, 1998, pp. 159-167, Vol. 164	
OC.	131	YARNALL, et al., Isolation and partial characterization of a type II Fc receptor from a group A streptococcus, Molecular and Cellular Biochemistry, 1986, pp. 57-66, Vol. 70	
Cel	7 132	CISANI, et al., High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme, Antimicrobial Agents and Chemotherapy, April 1982, pp. 531-535, Vol.21, No. 4	
		/~/O 1	

Examiner Signature	That	Date Considered	4-22-04	
-----------------------	------	--------------------	---------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUN 2 5 \$003

Sheet

WFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

stitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known Application Number 10/067,979 Filing Date 2/8/02 Vincent Fischetti First Named Inventor 1651 Group Art Unit PRATS, FRANCISCO CHANDLER Examiner Name Attorney Docket Number

			U.S. PATENT	OCUMENTS		
Examiner C	Cite	Document Number	Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials *	No.1	Number - Kind Code ² (if known)		Line Do Voor		
$\mathcal{B}\mathcal{W}$	133	US-5605793	02/25/97	Stemmer		
	134	US- 6355477	03/12/02	Fischetti et al		
	135	US- 6331405	12/18/01	Rambukkana et al	DEOF	
	136	US- 6190659	02/20/01	Pancholi et al	RECEIVE	
	137	US- 5985654	11/16/99	Fischetti et al		
	138	US- 5842314	11/24/98	Scott et al	LIN 9 & MUL	
	139	US- 5910441	08/08/99	Rocha et al	2 € €98)	
	140	US- 5786205	07/28/98	Fischetti et al	MFALL DOWN	
	141	US- 5976792	11/02/99	Cheung et al	TECH CENTER 1600/2	
	142	US- 5821088	10/13/98	Darzins et al		
	143	US- 5723303	03/03/98	Fischetti et al		
	144	US- 5643767	07/01/97	Fischetti et al		
	145	US- 5707822	01/13/98	Fischetti et al		
	146	US- 5616686	04/01/97	Fischetti et al		
	147	US- 5604109	02/18/97	Fischetti et al		
	148	US- 5587288	12/24/96	Cheung et al		
	149	US- 5556944	09/17/96	Fischetti et al		
/	150	US- 5352588	10/04/94	Fischetti et al		
(//	151	US- 5968763	10/19/99	Fischetti et al		
V	152	US- 4784948	11/15/88	Scott et al		

FOREIGN PATENT DOCUMENTS						
	Examiner Cite Initials* No.1 Cou	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				T°
KI	153	WO 03/024410 A2	03/27/03	Fischetti et al		
01						
						_

Examiner Signature	1	4-22-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.